Skip to main content

Table 1 Clinical characteristics, laboratory data, and imaging results at ICU admission

From: Nafamostat mesylate treatment in combination with favipiravir for patients critically ill with Covid-19: a case series

Characteristic Measurement
Age, median (IQR), years 68 (60–69)
Male, no. (%) 10 (91%)
Body weight, median (IQR), kg 71 (69–82)
Number of patients with coexisting disorders, no. (%)
 Asthma 0 (0%)
 Cancer 1 (9%)
 Chronic kidney disease 0 (0%)
 Chronic obstructive pulmonary disease 1 (9%)
 Diabetes mellitus 3 (27%)
 Hypertension 4 (36%)
Duration of symptoms before admission, median (IQR), days 8 (7–11)
Number of patients with symptoms, no. (%)
 Fever 9 (82%)
 Cough 5 (45%)
 Shortness of breath 8 (73%)
Laboratory data
 White blood cell count, median (IQR), per mm3 6900 (5800–10,850)
 Lymphocyte count, median (IQR), per mm3 851 (759–1164)
 Hemoglobin, median (IQR), g/dl 15.0 (13.5–16.3)
 Platelet count, median (IQR), per mm3 19.6 (18.6–26.4)
 Lactate dehydrogenase level, median (IQR), U/l 518 (417–752)
 Aspartate aminotransferase level, median (IQR), U/l 54 (49–90)
 Alanine aminotransferase level, median (IQR), U/l 47 (35–58)
 Serum creatinine level, median (IQR), mg/dl 0.85 (0.70–1.03)
 Creatinine kinase level, median (IQR), U/l 213 (129–579)
 Prothrombin time, median (IQR), international normalized ratio 1.08 (1.03–1.13)
 Activated partial thromboplastin time, median (IQR), s 28.8 (28.4–32.1)
d-dimer level, median (IQR), μg/dl 1.4 (1.1–11.8)
 PaO2/FiO2 ratio, median (IQR) 131 (114–198)
 SOFA score, median (IQR) 3.0 (2.5–4.5)
 APACHE II score, median (IQR) 14.0 (12.0–15.5)
Computed tomography findings
 Patients with consolidation, no. (%) 6 (55%)
 Patients with ground-glass opacities, no. (%) 10 (91%)
 Patients with pulmonary infiltration, no. (%) 2 (18%)
  1. APACHE Acute Physiology and Chronic Health Evaluation, FiO2 fraction of inspired oxygen, ICU intensive care unit, IQR interquartile range, PaO2 partial pressure of arterial oxygen, SOFA sequential organ failure assessment